Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Operating Expenses (2016 - 2025)

Guided Therapeutics' Other Operating Expenses history spans 16 years, with the latest figure at $23000.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 66.67% to $23000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $169000.0, a 41.11% decrease, with the full-year FY2025 number at $169000.0, down 41.11% from a year prior.
  • Other Operating Expenses hit $23000.0 in Q4 2025 for Guided Therapeutics, up from $22000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for GTHP hit a ceiling of $76000.0 in Q3 2024 and a floor of -$1000.0 in Q2 2022.
  • Historically, Other Operating Expenses has averaged $50250.0 across 5 years, with a median of $52000.0 in 2022.
  • Biggest five-year swings in Other Operating Expenses: tumbled 103.7% in 2022 and later skyrocketed 6200.0% in 2023.
  • Tracing GTHP's Other Operating Expenses over 5 years: stood at $34000.0 in 2021, then surged by 52.94% to $52000.0 in 2022, then increased by 25.0% to $65000.0 in 2023, then increased by 6.15% to $69000.0 in 2024, then crashed by 66.67% to $23000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for GTHP at $23000.0 in Q4 2025, $22000.0 in Q3 2025, and $51000.0 in Q2 2025.